Caspase-Glo 3/7 Assay Used to Assess Cardiotoxicity in hSC-Derived Cardiomyocytes

This article by scientists from Cellular Dynamics International, Inc. demonstrates the use of the Caspase-Glo® 3/7 Assay in cardiomyocytes derived from induced pluripotent human stem cells (iPS).

Beating stem-cell derived cardiomyocytes The advent of iPS technology increases the utility of stem cell-derived experimental models, and negates many of the ethical concerns surrounding embryonic stem cells. [wpvideo PJJgsmYh] Human pluripotent stem cell (hPSC)-derived cardiomyocytes display normal cardiac characteristics, survive under cell culture conditions for extended periods and thus hold the potential to serve as a human-based model for both drug development and cardiotoxicity screening. The electrical activity and controllable environmental conditions of hPSCcardiomyocytes provide an ideal model for both drug development and toxicity testing. In addition to being useful for seeing changes in action potentials, hPSCcardiomyocytes are readily amenable to assessing toxic endpoints such as cell viability, apoptosis, ATP production/metabolism, and mitochondrial dysfunction through readily available test kits. In this article, the authors demonstrate the utility of hSC-derived cardiomyocytes for detecting apoptosis and cytotoxicity.

Video kindly provided by Cellular Dyanmics International, Inc.

The following two tabs change content below.

Michele Arduengo

Senior Content Developer / Social Media Lead at Promega Corporation
Michele earned her B.A. in biology at Wesleyan College in Macon, GA, and her PhD through the BCDB Program at Emory University in Atlanta, GA. Michele manages the Promega Connections blog. She enjoys leisure reading, writing creative nonfiction and knitting, and the occasional cross-country skiing jaunt.

Latest posts by Michele Arduengo (see all)

Leave a Reply